Robotic urologic surgery using the Toumai MT-1000 Endoscopic Surgical System: a single-center prospective analysis.

Abstract

Background: The Toumai MT-1000 Endoscopic Surgical System is a newly developed surgical robot from China. This study evaluates its feasibility, safety, and effectiveness for various urologic procedures based on our single-center experience.

Methods: From October 2023 to January 2024, 20 urologic procedures were performed at Peking University First Hospital using the Toumai MT-1000 system. Clinical features, perioperative data, and follow-up outcomes were prospectively collected and analyzed.

Results: The procedures included five partial nephrectomies (PN), five adrenalectomies, five upper urinary tract (UUT) reconstructions, four radical prostatectomies (RP), and one radical cystectomy (RC). The median operative times were 175.0 min for PN, 167.4 min for adrenalectomy, 224.2 min for UUT reconstruction, 300.3 min for RP, and 374.0 min for RC. The median hemoglobin drops were 1.2 g/dL for PN, 1.3 g/dL for adrenalectomy, 1.2 g/dL for UUT reconstruction, 2.3 g/dL for RP, and 0.2 g/dL for RC. All procedures were successfully completed without conversion, and no major complications occurred. The median warm ischemia time for PN was 34.6 min, with no positive surgical margins. The positive surgical margin rate for RP was 25% (1/4), with no biochemical recurrence observed during the 3-month follow-up. The surgical success rate for UUT reconstruction was 100% over 3 months.

Conclusions: The Toumai MT-1000 Endoscopic Surgical System has demonstrated safety and efficacy in urological procedures. It represents a viable option for further clinical research, offering promising prospects due to its advanced features that enhance surgeon comfort.